[go: up one dir, main page]

MX2020002266A - Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos. - Google Patents

Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.

Info

Publication number
MX2020002266A
MX2020002266A MX2020002266A MX2020002266A MX2020002266A MX 2020002266 A MX2020002266 A MX 2020002266A MX 2020002266 A MX2020002266 A MX 2020002266A MX 2020002266 A MX2020002266 A MX 2020002266A MX 2020002266 A MX2020002266 A MX 2020002266A
Authority
MX
Mexico
Prior art keywords
adcs
egfr
drug conjugates
adc
egfr antibody
Prior art date
Application number
MX2020002266A
Other languages
English (en)
Inventor
Edward Reilly
Mark Anderson
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2020002266A publication Critical patent/MX2020002266A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación proporciona conjugados fármaco-anticuerpo (ADC) que comprenden un agente citotóxico o citoestático ligado a un anticuerpo anti-EGFR mediante un ligador, composiciones que comprenden los ADC, métodos de elaboración de los ADO, y métodos para tratar un tipo de cáncer que comprenden administrar los ADC a un sujeto que tiene cáncer. La presente divulgación proporciona ADC que se fijan específicamente al EGFR y, en particular, al EGFR humano (hEGFR). EI Ab anti-EGFR descrito en la presente comprende una mutación 8239C en una región constante de la cadena pesada, en donde la numeración es de acuerdo con Kabat.
MX2020002266A 2017-09-02 2018-09-04 Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos. MX2020002266A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762553840P 2017-09-02 2017-09-02
PCT/US2018/049409 WO2019046858A1 (en) 2017-09-02 2018-09-04 ANTI-EGFR-DRUG ANTIBODY (ADC) CONJUGATES AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020002266A true MX2020002266A (es) 2021-01-08

Family

ID=65526046

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002266A MX2020002266A (es) 2017-09-02 2018-09-04 Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.

Country Status (9)

Country Link
US (1) US20200297863A1 (es)
EP (1) EP3675908A4 (es)
JP (1) JP2020532543A (es)
CN (1) CN111278462A (es)
AU (1) AU2018326877A1 (es)
BR (1) BR112020004225A2 (es)
CA (1) CA3073331A1 (es)
MX (1) MX2020002266A (es)
WO (1) WO2019046858A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11123494B2 (en) 2017-08-22 2021-09-21 KB Medical, LLC Exostructure to assist in accurate syringe injection
EP3927398A4 (en) * 2019-02-19 2022-11-02 KB Medical, LLC EXOSTSTRUCTURE TO SUPPORT ACCURATE SYRINGE INJECTION
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR20250129814A (ko) 2023-01-18 2025-08-29 타이리간드 바이오사이언스 (상하이) 리미티드 항체-약물 접합체 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5870400B2 (ja) * 2010-04-15 2016-03-01 シアトル ジェネティクス，インコーポレーテッド 標的化ピロロベンゾジアゼピンコンジュゲート
SI3461847T1 (sl) * 2010-12-06 2021-03-31 Seagen Inc. Humanizirana protitelesa proti LIV-1 in njihova uporaba pri zdravljenju raka
ES2704411T3 (es) * 2013-03-12 2019-03-18 Biocon Ltd Proteínas de fusión inmunomoduladoras y procedimientos de fabricación de las mismas
KR20220025946A (ko) * 2014-03-21 2022-03-03 애브비 인코포레이티드 항-ｅｇｆｒ 항체 및 항체 약물 접합체
ES2719584T3 (es) * 2014-04-11 2019-07-11 Medimmune Llc Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína
US20190083645A1 (en) * 2015-12-04 2019-03-21 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use

Also Published As

Publication number Publication date
CN111278462A (zh) 2020-06-12
EP3675908A4 (en) 2021-05-12
US20200297863A1 (en) 2020-09-24
WO2019046858A1 (en) 2019-03-07
BR112020004225A2 (pt) 2020-09-08
AU2018326877A1 (en) 2020-03-05
CA3073331A1 (en) 2019-03-07
EP3675908A1 (en) 2020-07-08
JP2020532543A (ja) 2020-11-12

Similar Documents

Publication Publication Date Title
PH12020500417A1 (en) Anti-efgr antibody drug conjugates (adc) and uses thereof
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
ZA201907233B (en) Conjugation of a cytotoxic drug with bis-linkage
MX2024008464A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
MX2020013832A (es) Conjugados de ligante/agente activo dirigidos contra cxcr5 que tienen enlazadores escindibles enzimaticamente y un perfil de actividad mejorado.
PE20120556A1 (es) Inmunoconjugados anti-mesotelina
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
MX2025001919A (es) Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
NZ748314A (en) Anti-cmet antibody drug conjugates and methods for their use
MX2020002266A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos.
PH12022551036A1 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MX2021015974A (es) Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados.
MX2022015375A (es) Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
PE20221459A1 (es) Conjugados anticuerpo-farmaco dirigido a claudina 18.2
WO2018119196A8 (en) Immunoconjugates targeting adam9 and methods of use thereof
MX2020008613A (es) Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer.
EA202190102A1 (ru) Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака
MX2020013466A (es) Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
MX2022003243A (es) Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos.
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
MX2025003663A (es) Anticuerpos anti-napi2b y metodos de uso
MX2023000499A (es) Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular.
CL2023003905A1 (es) Conjugados novedosos que comprenden fosfoantígenos y su uso terapéutico
WO2019089594A8 (en) Combination treatment with antibody-drug conjugates and cytarabine